Strategic platform Position Century Therapeutics’ allogeneic iPSC-derived cell therapy platform as a versatile foundation for collaborations with pharma companies seeking scalable, off-the-shelf solutions for autoimmune diseases and cancer.

Strong funding Leverage Century’s substantial funding and steady growth trajectory as a proof point for stability and long-term partnerships, enabling co-development or licensing deals and joint ventures with downstream value.

Executive leadership Highlight recent leadership appointments (CFO and CSO) and academic collaborations to build credibility with investors and potential collaborators, while aligning business development conversations around governance and scientific rigor.

Industry engagement Capitalize on active conference presence and preclinical data sharing (e.g., CNTY-813) to create targeted outreach opportunities with pharma and biotech decision-makers evaluating autoimmune and oncology pipelines.

Market positioning Differentiate through iPSC-derived, allogeneic therapies by offering accelerated timelines, scalable manufacturing capabilities, and potential cost advantages, appealing to partners seeking rapid, global deployment.